Sam Brusco, Associate Editor06.08.23
Catalyst OrthoScience has named seasoned medical device leader Mark Quick as its new chief financial officer (CFO) effective immediately.
With almost two decades of medical device experience, Quick was most recently at Orthofix where he served in financial leadership and business development roles of increasing responsibility. Before Orthofix, he was a sell-side equity research analyst covering the medical device industry at Canaccord Genuity.
“I am thrilled to join Carl and the rest of the talented Catalyst team in their commitment, dedication, and focus to providing differentiated solutions to shoulder surgeons and patients,” Quick told the press. “With its growing product portfolio, Catalyst is positioned to accelerate expansion of its distribution channel leading to broad adoption in the high-growth $1.5 billion U.S. shoulder replacement market.”
Catalyst recently earned U.S. Food and Drug Administration (FDA) 510(k) clearance for its fully convertible stemmed total shoulder arthroplasty system with ellipsoid anatomic head. It’s the market’s first such device and expands Catalyst’s portfolio to offer stemless, stemmed, and convertible shoulder replacement options.
“Mark brings a wealth of expertise in the medical device market to our team, and we are excited to leverage his decades of experience as we continue to grow,” said Carl O’Connell, CEO and president of Catalyst. “Our purposely designed approach to shoulder replacement surgery is focused squarely on solutions that better match the patient’s own anatomy, reduce complications and support the needs of surgeons for precision, accuracy and repeatability.”
With almost two decades of medical device experience, Quick was most recently at Orthofix where he served in financial leadership and business development roles of increasing responsibility. Before Orthofix, he was a sell-side equity research analyst covering the medical device industry at Canaccord Genuity.
“I am thrilled to join Carl and the rest of the talented Catalyst team in their commitment, dedication, and focus to providing differentiated solutions to shoulder surgeons and patients,” Quick told the press. “With its growing product portfolio, Catalyst is positioned to accelerate expansion of its distribution channel leading to broad adoption in the high-growth $1.5 billion U.S. shoulder replacement market.”
Catalyst recently earned U.S. Food and Drug Administration (FDA) 510(k) clearance for its fully convertible stemmed total shoulder arthroplasty system with ellipsoid anatomic head. It’s the market’s first such device and expands Catalyst’s portfolio to offer stemless, stemmed, and convertible shoulder replacement options.
“Mark brings a wealth of expertise in the medical device market to our team, and we are excited to leverage his decades of experience as we continue to grow,” said Carl O’Connell, CEO and president of Catalyst. “Our purposely designed approach to shoulder replacement surgery is focused squarely on solutions that better match the patient’s own anatomy, reduce complications and support the needs of surgeons for precision, accuracy and repeatability.”